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Abstract
Summary In this prospective cohort of 6120 participants aged 50+, nitrogen-bisphosphonates but not non-nitrogen
bisphosphonates were associated with a significant 34% mortality risk reduction compared to non-treated propensity score
matched controls. These findings open new avenues for research into mechanistic pathways.
Introduction Emerging evidence suggests that bisphosphonates (BP), first-line treatment of osteoporosis, are associated with
reduced risks for all-cause mortality. This study aimed to determine the association between different BP types and mortality risk
in participants with or without a fracture.
Methods A prospective cohort study of users of different BPs matched to non-users by propensity score (age, gender, co-
morbidities, fragility fracture status) and time to starting the BP medication from the population-based Canadian Multicentre
Osteoporosis Study from nine Canadian centres followed from 1995 to 2013. Mortality risk for bisphosphonate users vs matched
non-users was assessed using pairwise multivariable Cox proportional hazards models.
Results There were 2048 women and 308 men on BP and 1970 women and 1794 men who did not receive medication for
osteoporosis. The relationship between BP and mortality risk was explored in three separate 1:1 propensity score-matched
cohorts of BP users and no treatment (etidronate, n = 599, alendronate, n = 498, and risedronate n = 213). Nitrogen BP (n-BP)
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(alendronate and risedronate) was associated with lower mortality risks [pairwise HR, 0.66 (95% CI, 0.48–0.91)] while the less
potent non-n-BP, etidronate, was not [pairwise HR: 0.89 (95%CI, 0.66–1.20)]. A direct comparison between n-BP and etidronate
(n = 340 pairs) also suggested a better survival for n-BP [paired HR, 0.47 (95%CI, (95% CI, 031–0.70)] for n-BP vs. etidronate].
Conclusion Compared to no treatment, nitrogen but not non-nitrogen bisphosphonates appear to be associated with better
survival.
Keywords Bisphosphonate . Fracture . Mortality risk . Osteoporosis . Prospective study
Introduction
Osteoporotic fragility fracture is highly prevalent in the general
population and is associated with serious consequences. From
the age of 50, 40% of women and 25% of men will sustain a
fragility fracture (trauma less than or equal to a fall from stand-
ing) during their remaining lifetimes [1]. Men andwomenwith
a fracture have increased risk of further fractures [2–4] and
most importantly, premature mortality [5–7]. Despite the avail-
ability of effective medications, treatment rates continue to be
lowwith < 30%women and < 20%menwith fragility fractures
on validated treatments. Bisphosphonates, first-line treatment
for osteoporosis world-wide [8, 9], are effective in reducing the
relative risk of fracture by between 40 and 70% [10] and also
appear to confer a survival benefit among patients with a frac-
ture [11, 12] based on a randomised controlled trial (RCT) of
hip fracture patients [13–15] and several cohort [16–18],
registry-based studies [14, 15], and more recently in a
Fracture Liaison Service setting [19]. In the RCT, hip fracture
subjects given zoledronic acid had a 28% reduced mortality
[11]. A meta-analysis of anti-osteoporosis medications from
eight RCTs found a pooled mortality risk benefit (~ 11%) of
these agents [12]. More recently, zoledronic acid was reported
to reduce mortality risk by 35% [OR 0.65 (95% CI, 0.40–
1.05)] over 6 years in a RCT of women with osteopenia [20].
Despite multivariate adjustment, criticism persists that, at
least in cohort studies, survival benefit may relate to healthy
user bias; however, RCTs with mortality as the primary out-
come will likely not be conducted due to necessary large num-
bers, expense and particularly ethical considerations. This is-
sue is important to resolve as, if true, it may help to increase the
acceptability and uptake of urgently needed treatments [21]. A
scenario in which any potential bisphosphonate-related mortal-
ity benefit could be further explored, would therefore be a
cohort study that examines the effect of bisphosphonates of
different chemistries expected to have different effects on all-
cause mortality. Thus if a difference were found, any healthy
user bias would be avoided as indications for treatment would
be similar.
There are two main classes of bisphosphonates: nitrogen
bisphosphonates (n-BP, e.g. alendronate, risedronate) and
non-n-BP (e.g. etidronate). The newer bisphosphonates (n-
BP) have a different mechanism of action and are more potent
than the non-nitrogen bisphosphonates [22, 23]. The higher
potency of n-BP result in a greater reduction of bone loss that
would limit the resorption-related release from bone of toxic
substances (e.g. lead) [24, 25]. Furthermore, several studies
have suggested that n-BP may have non-bone beneficial ef-
fects such as on immune function [26, 27] (although adverse
immune effects also occur [28]), endothelial function [29],
systemic inflammation [30], and an antitumor effect [31].
Our hypothesis was that participants on bisphosphonates
would have a better survival than those on no treatment and
that themore potent nitrogen-bisphosphonate may have a great-
er effect than the non-nitrogen bisphosphonates. This study
therefore examined the association between bisphosphonates
of two different chemistries with all-cause mortality in a




The study population consisted of women and men partic-
ipating in the Canadian Multicentre Osteoporosis Study
(CaMos), an ongoing prospective population-based study
that started in 1995 with the aim to document the skeletal
health of a randomly selected population of women and
men aged 25 and over. All non-inst i tut ionalised
Canadians who resided within 50 km of a study centre,
representing ~ 37% of all Canadians were eligible.
Participants were recruited using randomly generated tele-
phone lists from the region surrounding nine urban centres
in Canada. A detailed description of the study design and
population sampling has been published previously [32].
CaMos was approved by the Ethics Committee of McGill
University and at each participating centre.
Of the 9423 participants recruited, 7689 aged 50+ were
screened for medication uptake. CaMOS is an observational
study, thus all the medication was initiated by each partici-
pant’s physician without any intervention from the CaMOS
investigators. Etidronate and alendronate received Canadian
regulatory approval for osteoporosis treatment within a year of
each other, and prior to the start of CaMOS. In most Canadian
provincial drug plans, access to alendronate (and risedronate)
was restricted to patients who had already suffered an
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osteoporotic fracture; or had either failed to respond to etidro-
nate (had lost bone density or suffered a new fracture) or were
not able to tolerate etidronate. This is reflected in this obser-
vational study by the large number of participants (~ 40%)
who switched between bisphosphonate types during the
follow-up (Fig. 1). To account for any potential immortal time
bias induced by this switch, the primary aim was investigated
in the groups not treated versus those treated with only one
type of bisphosphonate for the entire follow-up.
Inclusion criteria Individuals who used bisphosphonates dur-
ing the study follow-up (etidronate, alendronate, and
risedronate), and those who did not use any osteoporosis-
related medication (NoRx) were included.
Exclusion criteria A number of osteoporosis-related medica-
tions were excluded due to small number of users (clodronate,
n = 22, pamidronate, n = 54, zoledronic acid, n = 44, calcito-
nin, n = 14, denosumab, n = 2, raloxifene, n = 50), tamoxifen
(n = 100), and testosterone (n = 39) (Fig. 1). A relatively large
number of women reported hormone therapy (N = 1268) at
baseline or throughout the study (Fig. 1). This group of women
had more favourable characteristics than women who did not
take any medication. They were younger, had higher BMD, a
higher proportion of distal compared to proximal fractures, and
also had better lifestyle habits (less smoking, more exercise,
andmore were taking vitamin D). Given the unknown duration
of prior exposure and the potential effect on cardiovascular
risk, this group was excluded from further analyses; however,
1569*
W=1508  M=61
7689 Participants 50+ from CaMos enrolled1995-1997












745 Alendronate (W=650, M=95)
274 Risedronate (W=228, M=46)
1337 Etidronate (W=1170, M=167)
Participants (W=4018, M=2102)
3764 No Treatment (W=1970, M=1794)
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* The individual numbers do not add up to the total as some individual used more than one medication and thus listed more than once
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498 Alendronate (W=425, M=73)
237 Risedronate (W=194, M=43)








Fig. 1 Flow chart of participants aged 50+ from Canadian Multicentre Osteoporosis Study
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after adjustment for baseline characteristics, their survival was
not significantly better than those on no treatment.
Outcomes and risk factors
A standardised interviewer-administered questionnaire was
obtained at baseline (1995–1997). Information was obtained
on lifestyle factors (i.e. smoking, physical activity), demo-
graphics, education, co-morbidities, and medication use. In
addition to this structured questionnaire, each participant had
a clinical visit that included anthropometric measurements
(i.e. height, weight) and femoral neck areal bone mineral den-
sity (BMD). This information was subsequently obtained in
years 3 (40–60 years of age only), 5 and 10. Yearly postal self-
administered questionnaires for incident fractures and medi-
cations were obtained between clinical visits.
Bisphosphonate exposure
Bisphosphonate uptake was determined from yearly question-
naires and the inventory of medications brought to each inter-
view (baseline and years 3, 5 and 10). Participants were classi-
fied as bisphosphonate users based on yearly report of medica-
tion. Of the 2356 eligible bisphosphonate users, 985 participants
used more than one type of bisphosphonate (Fig. 1). Thus, 50%
participants initiated on etidronate, 33% on alendronate and
14% on risedronate switched during the study follow-up to
another class of bisphosphonate. These participants were in-
cluded in a sensitivity analysis, classified according to the first
bisphosphonate used. The treatment initiation date was taken as
the year of the first reported use of bisphosphonate.
The uptake of bisphosphonate during follow-up was much
lower in men (~ 14%) then women (~ 40%). Therefore, we
have performed two analyses: Bany user^ including both gen-
ders, and women only.
Adherence to bisphosphonates was not recorded.
Participants who reported bisphosphonates only once during
the follow-up (n = 251) were used as surrogate for non-
adherence in a sensitivity analysis.
Participants did not receive any formal fracture risk assess-
ment or management suggestions from the CaMOS investiga-
tors. They, and/or their primary care physician received a copy
of the BMD report performed at baseline and all subsequent
visits.
Fracture ascertainment
Self-reported incident clinical fractures were obtained yearly
and at clinical visits. Information on the date, site, circum-
stance of the fracture, and an x-ray report was obtained by
interview. Medical records were obtained and verified for
78% of fractures.
This study included only incident fragility fractures. Skull,
sternum, finger and toe fractures were excluded.
Mortality ascertainment
Mortality ascertainment was conducted annually throughout
the study follow-up. All participants provided contact detail
for next of kin. If a participant did not respond to the yearly
questionnaire, the study co-ordinator contacted the next of
kin. If this failed, obituaries were screened for death records.
Although mortality data were not formally validated using
national figures or other external data sources, it was highly
unlikely that these deaths were misclassified.
Statistical analysis
Baseline characteristics were examined for BP (alendronate,
risedronate and etidronate) in comparison to NoRx (t tests for
continuous and chi2-square tests for categorical variables).
Whole cohort
For the primary analysis, participants who used only one type
of bisphosphonate during the follow-up (n = 1371), classified
as n-BP (alendronate and risedronate) and non-n-BP etidro-
nate were matched 1:1 to non-treated participants. Matching
was by a propensity score, including age, gender, fracture
type, co-morbidities and life-style factors that predicted the
likelihood of being treated [33], and time to starting medica-
tion. Follow-up was calculated from the time of medication
start for both treated and non-treated. For non-treated, this
starting point was obtained by the addition to baseline date
his/her Bpair’s^ time of medication commencement. This pro-
cedure ensured that all participants had similar baseline char-
acteristics, avoiding selection bias, and that a participant who
started treatment later during the follow-up was matched to a
control still alive at that time point, avoiding immortal time
bias. Mortality risk was analysed using a paired Cox propor-
tional hazards model. Proportionality hazards assumption was
tested by the inspection of Schoenfeld residuals over time.
Kaplan Meier survival curves for each bisphosphonate were
also created.
Subgroup and sensitivity analysis
To determine the role of individual bisphosphonate type on
mortality risk, alendronate and risedronate users were sepa-
rately compared to no treatment using a paired Cox propor-
tional hazards model adjusted for any variable which became
unbalanced after stratification.
To test the hypothesis that n-BPs have, a stronger associa-
tion with mortality reduction than the non-n-BPs, a head-to-
head comparison between the 2 classes of bisphosphonates
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was performed in a set of n-BP matched 1:1 to etidronate by
propensity score, using a paired Cox Proportional Hazards
Model.
A sensitivity analysis including all bisphosphonate users
(n = 2356), with switchers classified according to initial type
of bisphosphonate was performed using inverse probability
weighting with treatment as a time-dependent variable. The
period of time prior to treatment initiation contributed to no
treatment, while the interval following the first bisphospho-
nate uptake contributed to treatment, in an intention to treat
analysis. Thus, all bisphosphonate users were classified ac-
cording to the initial type of bisphosphonate, regardless if they
continued on the same bisphosphonate, or switched to another
type during the follow-up.
Individuals who reported bisphosphonate only at one visit
during the follow-up (n = 241), were used as surrogate for
non-adherence and excluded in a sensitivity analysis.
Fracture cohort
A subset analysis of the relationship between the bisphospho-
nate initiated at or following the time of fracture and mortality
was performed for individuals with incident fractures. n-BP
and etidronate users were matched 1:2 by age, gender and
fracture type to individuals who did not use any treatment after
the incident fracture. Fracture risk was assessed for all indi-
viduals using the Garvan fracture risk calculator [34]. The
relationship between BP and survival was assessed using a
paired Cox Proportional Hazard Model.
Subgroup analysis
Given the high mortality occurring immediately after the frac-
ture event, this analysis was also performed according to the
time of BP initiation post-fracture (0–2, 2–5) and 5+ years in
n-BP group only, due to small number of etidronate users 2+
years post-fracture.
In order to examine whether the mortality reduction could
be mediated by a reduction in subsequent fracture events, an
additional Cox proportional hazards model with subsequent
fracture as the outcome was conducted.
All statistical analyses were performed using SAS 9.4 and
R statistical environment on a Windows platform. There were
no missing values for the main outcome measurement (i.e.
deaths). Missing variables were inputted using the R-
Package Mice [35]. The plausible values of missing data for
the covariates were imputed using multivariate imputation by
chained equations algorithm (MICE) which created five com-
pleted imputed datasets. Each variable has its own imputation
equation. The MICE method uses all variables in the dataset,
including the outcome of interest for imputation of missing
data via chained regression equations algorithm.
Results
Cohort characteristics
This study included 4018 women and 2102 men aged 50+
followed for a median of 13.5 (IQR: 6.5–15.0) and 12.5 years
(IQR: 5.4–15.0) for women and men, respectively.
During the follow-up, 1081 (27%) women and 284 men
(14%) experienced an incident fracture, 308 women and 53 in
men experienced a further fracture and 899 women and 578
men died. The length of follow-up post-fracture was 5.5 (IQR:
2.6–9.5) and 5.1 years (IQR: 2.3–9.9) for women and men,
respectively.
Approximately, 65% of women and 23% of men had oste-
oporosis at baseline (femoral neck T-score ≤ − 2.5 SD). Of
those with baseline osteoporosis, 60% of women and 29%
of men received bisphosphonate medication during follow-
up. Male gender, baseline diabetes and cardio-vascular dis-
ease, smoking, physical inactivity and lower level of educa-
tion were associated with a higher likelihood of not receiving
bisphosphonate therapy. A greater number of medications at
baseline did not represent a barrier to receiving bisphospho-
nate therapy.
Treatment groups
Reflecting Canadian practice at baseline, etidronate was the
most frequently prescribed bisphosphonate [1170 (57%) for
women and 167 (54%) for men] followed by alendronate [650
(32%) for women and 95 (31%) for men], and risedronate
[228 (11%) for women and 46(15%) for men] (Table 1).
Risedronate only became available in 1999 and was started
on average ~ 9 (± 3) years after baseline resulting in both the
smaller number of risedronate users and shorter follow-up: 5
(± 3) years compared to 8 (± 4) years for alendronate and 9 (±
4) years for etidronate.
Bisphosphonate users had significantly lower femoral neck
BMD, weight, and more incident fractures than NoRx. They
also had several factors associated with Bhealthy users^ such
as better education lifestyle habits (less smoking, more exer-
cise and more vitamin D use) and less cardiovascular disease
and diabetes. There were no substantive differences in bis-
phosphonate uptake and year of initiation for the nine study
centres across Canada (see supplemental table (Table S1).
Bisphosphonate type and mortality for individuals
with and without fracture n-BP (alendronate
and risedronate) vs NoRx
Of the 735 n-BP users, 635 (83% women) were matched to
NoRx (Table 2). After propensity score matching, there were
no statistically significant differences in baseline characteris-
tics between treated and not treated. Mortality risk was
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Table 1 Characteristics of
participants according to
medication-groups
Bisphosphonate type No treatment
Alendronate Risedronate Etidronate
Women
Number 650 228 1170 1970
Agea, yrs. 66 (8) 65 (8) 68 (8) 70 (10)
Deathb 92 (14) 22 (10) 242 (21) 543 (28)
Weighta, kg 64 (12) 65 (11) 65(12) 71 (15)
Higher educationb 174 (27) 50 (22) 236 (20) 335 (17)
Year of initiation 1996 1999 1995
Years on medicationa 7 (4) 5 (3) 7 (4) N/A
Fractures1,b 243 (37) 72 (32) 414 (35) 352 (18)
Hip 25 (10) 6 (8) 52 (13) 50 (14)
Vertebral 47 (19) 9 (13) 50 (12) 25 (7)
Proximal2 81 (33) 19 (26) 131 (32) 102 (29)
Distal3 90 (37) 38 (53) 181 (44) 175 (50)
BMD4,a, g/cm2 0.63 (0.10) 0.67 (0.09) 0.63 (0.09) 0.71 (0.12)
Co-morbiditiesb
Heart disease 40 (6) 34 (15) 199 (17) 233 (12)
Diabetes 46 (7) 23 (10) 85 (7) 320 (16)
Hypertension 251 (39) 104 (46) 537 (46) 993 (51)
Neurological 21 (3) 9 (4) 53 (5) 64 (3)
Respiratory 98 (15) 28 (13) 186 (16) 264 (14)
Cancer 115 (18) 34 (15) 213 (18) 297 (15)
Life style factorsb
Exercise 409 (63) 139 (69) 679 (58) 972 (49)
Smoking 76 (12) 27 (12) 131 (11) 302 (15)
Vitamin D 256 (39) 75 (33) 453 (39) 546 (28)
Men
Number 95 46 167 1794
Agea, yrs. 64 (9) 65 (8) 69 (9) 66 (10)
Deathb 22 (23) 11 (24) 54 (32) 491 (27)
Weighta, kg 79 (12) 79 (13) 76 (12) 82 (14)
Higher educationb 39 (41) 17 (37) 49 (29) 595 (33)
Year of initiation 1997 1999 1996
Years on medicationa 5 (4) 4 (3) 6 (4) N/A
Fractures1,b 24 (25) 8 (17) 39 (22) 213 (12)
Hip 6 (25) 0 (0) 10 (25) 32 (15)
Vertebral 1 (4) 0 (0) 4(10) 16 (8)
Proximal2 10 (42) 7 (88) 11 (28) 88 (41)
Distal3 7 (29) 1 (12) 14 (36) 77 (36)
BMD4,a, g/cm2 0.71 (0.11) 0.72 (0.11) 0.69 (0.11) 0.81 (0.12)
Co-morbiditiesb
Heart disease 14 (15) 5 (11) 18 (11) 293 (16)
Diabetes 10 (11) 6 (13) 18 (11) 297 (17)
Hypertension 35 (36) 22 (48) 67 (40) 728 (41)
Neurological 1 (1) 1 (2) 4 (2) 48 (3)
Respiratory 13 (14) 9 (20) 21 (13) 201 (11)
Cancer 17 (18) 8 (17) 39 (23) 265 (15)
Life style factorsb
Exercise 52 (55) 23 (50) 87 (52) 1002 (56)
Smoking 12 (13) 9 (20) 23 (14) 336 (19)
Vitamin D 27 (28) 9 (20) 52 (31) 358 (20)
Boldface corresponds to a global p value < 0.05 for the comparison between treated (alendronate, risedronate,
etidronate) and not treated)
aMean (sd)
b Number (%)
1 Incident fragility fractures
2 Proximal fractures: humerus, elbow, pelvis, femur
3Distal fractures: forearm, carpal, metacarpal, tibia/fibula, ankle, tarsal, metatarsal
4 Femoral neck BMD missing values: weight 3%, BMD (13%), heart disease 0.001%, diabetes (0.001%), hyper-
tension (4%), respiratory (13%)
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reduced for the treated group [HR, 0.66 (95%CI, 0.48–0.91)],
in particular for women [HR, 0.58 (95% CI, 0.39–0.84)].
Subgroup analysis according to n-BP type
In order to determine whether the relationship between treat-
ment and survival was similar for the two nitrogen
bisphosphonates, a secondary analysis was performed sepa-
rately for alendronate and risedronate. In these models, mor-
tality risk was adjusted for the baseline characteristics unbal-
anced after stratification (i.e. cancer for alendronate group;
weight and smoking for risedronate group).
Alendronate users were associated with mortality risk re-
duction [HR 0.62 (95% CI, 0.42–0.92) for any user and 0.60
(95% CI, 0.38–0.93) for women only] (Table 3 and Fig. 2).
Risedronate was not associated with an overall mortality
risk reduction [HR 0.97 (95% CI, 0.50–1.88)]; however,
women who used risedronate appeared to have a mortality
risk reduction compared to NoRx [HR, 0.52 (0.25–1.09)]
(Table 3 and Fig. 2), albeit not statistically significant due to
low numbers.
Etidronate vs NoRx
Of the 663 etidronate users, 599 (83% women) were matched
to NoRx. By contrast with n-BP users, mortality rates of eti-
dronate users were similar to the matched NoRx [103 deaths/
3535 person-years equating to 2.91 deaths/100 person-years
(95% CI, 2.40–3.53) vs 110 deaths/3355 person-years equat-
ing to 3.28 deaths/100 person-years (95% CI, 2.72–3.95) for
Table 2 Characteristics of the
treated and not-treated matched
pairs of women by use of a single
specific bisphosphonate
n-BP vs not treated pairs Etidronate vs not
treated pairs
n-BP vs etidronate pairs
Women
Treated Not treated Treated Not treated n-BP Etidronate
Number 530 530 496 496 340 340
Agea, yrs. 66 (8) 66 (8) 68.9 (8.2) 68.9 (8.2) 68 (7) 68 (7)
Deathb 64 (12) 87 (16) 103 (21) 110 (22) 39 (11) 62 (18)
Weighta, kg 64 (11) 70 (14) 66.0 (12.9) 67.5 (13.5) 65 (11) 65 (11)
Higher educationb 126 (24) 122 (23) 93 (19) 93 (19) 61 (18) 55 (16)
Years on medication 6 (4) – 5 (4) – 4.9 (3.4) 5.5 (3.4)
Fractures1,b 140 (26) 140 (26) 105 (21) 105 (21) 113 (33) 95 (28)
Hip 10 (7) 10 (7) 11 (10) 11 (10) 13 (4) 11 (3)
Vertebral 6 (4) 6 (4) 5 (5) 5 (5) 17 (5) 5 (1)
Proximal2 45 (38) 45 (38) 37 (35) 37 (35) 31 (9) 33 (10)
Distal3 79 (51) 79 (51) 52 (50) 52 (50) 52 (15) 46 (14)
BMD4a, g/cm2 0.66 (0.10) 0.68 (0.10) 0.64 (0.09) 0.65 (0.09) 0.65 (0.10) 0.64 (0.09)
Co-morbiditiesb
Heart disease 27 (5) 32 (6) 51 (10) 44 (9) 32 (9) 29 (9)
Diabetes 18 (3) 27 (5) 41 (8) 49 (10) 28 (8) 26 (8)
Neurological 13 (2) 20 (4) 14 (3) 17 (3) 12 (4) 14 (4)
Respiratory 38 (8) 52 (11) 79 (16) 72 (15) 44 (13) 46 (14)
Cancera 92 (17) 112 (21) 88 (17) 93 (19) 58 (17) 62 (18)
Life style factorsb
Exercise 319 (60) 326 (62) 280 (56) 291 (59) 211 (62) 201 (59)
Smoking 67 (13) 83 (16) 65 (13) 60 (12) 40 (12) 45 (13)
Vitamin Da 188 (35) 156 (29) 174 (35) 137 (28) 123 (36) 124 (36)
Bold face corresponds to a global p value < 0.05 for comparison between treated and not treated within each pair
aMean (sd)
b Number (%)
1 Incident fragility fractures
2 Proximal fractures: humerus, elbow, pelvis, femur
3Distal fractures: forearm, carpal, metacarpal, tibia/fibula, ankle, tarsal, metatarsal
4 Femoral neck BMD
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etidronate and matched NoRx, respectively; p = 0.33)]
(Table 3 and Fig. 2). Etidronate use was not associated with
survival benefit in whole group [HR, 0.89 (95% CI, 0.66–
1.20)] or in women only [HR 0.88 (95% CI, 0.63–1.25)]
(Table 3).
The exclusion of participants who reported bisphosphonates
(n-BP or etidronate) only once during the follow-up, did not
change the findings.
Importantly, close inspection of the 2-year KM plots for
both n-BP and etidronate matched sets revealed that there
was no difference in survival during the first 6 months, sug-
gesting that the groups were well matched for mortality risk
prior to treatment initiation.
n-BP (alendronate and risedronate) vs etidronate
Given the differences in the baseline characteristics between
bisphosphonate types, reflecting different indication criteria,
only a third of n-BP users (n = 340) were successfully
matched 1:1 to etidronate (n = 340) by propensity score
(Table 2). After matching, all characteristics were balanced;
however, n-BP users had a borderline higher bone mineral
density [0.65 g/cm2 (0.10) and 0.64 g/cm2 (0.09); p = 0.07
for n-BP and etidronate, respectively] and a shorter duration
on medication [average 4.9 (± 3.4) years and 5.5 (± 3.4) years;
p = 0.03 for n-BP and etidronate, respectively]. Mortality risk
was significantly lower for n-BP users compared to etidronate
[paired HR, 0.47 (95% CI, (95% CI, 031–0.70)] (Fig. 3).
Sensitivity analysis
In the analysis of all the bisphosphonate users, including those
who switched to a different type of bisphosphonate, the results
were comparable to the single user analysis. n-BP use was
associated with 30–50% mortality risk reduction in the unad-
justed [HR, 0.58 (95% CI, 0.48–0.72)], and BMD-adjusted
Table 3 Mortality rates and hazard ratio for pairs of participants treated with different bisphosphonates propensity matched 1:1 to those who were not
treated
N Treated Not treated Paired HRa (95% CI)
(treated vs not treated)
Pairs Deaths Mortality rates
(/100 person-year) (95% CI)
Deaths Mortality rates
(/100 person-year) (95% CI)
n-BP 530 64 (12) 1.80 (1.41–2.30) 87 (16) 2.94 (2.39–3.63) 0.58 (0.39–0.84)
Alendronate 356 46 (13) 1.73 (1.29–2.31) 61 (17) 2.78 (2.16–3.57) 0.60 (0.38–0.94)
Risedronate 174 18 (10) 2.03 (1.28–3.22) 26 (15) 3.42 (2.32–5.01) 0.67 (0.30–1.49)
Etidronate 496 103 (21) 2.91 (2.40–3.53) 110 (22) 3.28 (2.72–3.95) 0.88 (0.63–1.25)





























































Ratio treated: Not Treated 1:1
Fig. 2 Kaplan-Meier survival curves for alendronate, risedronate and etidronate and matched not treated
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[HR, 0.66 (95% CI, 0.52–0.83)] analyses. Etidronate use was
not associated with mortality risk reduction in unadjusted
[HR, 0.99 (95% CI, 0.84–1.14)] or BMD-adjusted [HR,
1.18, 95% CI, 0.99–1.40)] analyses. Low BMD was a signif-
icant confounder in the model of etidronate and survival. A
stratified analysis according to BMD level, demonstrated that
etidronate was associated with increased mortality risk for
osteoporosis group [HR, 1.28 (95% CI, 1.06–1.54)], and a
non-significant survival benefit for normal/osteopenia group
[HR, 0.72 (95% CI, 0.46–1.15)].
However, when the models where adjusted for inverse
treatment probability scores, both n-BP and etidronate users
were associated with survival benefit [HRs, 0.50 (95% CI,
0.39–0.63) and 0.69 (95% CI, 0.59–0.82), for n-BP and eti-
dronate, respectively].
Bisphosphonate type and mortality for women
with incident fracture
Of the 1081 women with incident fracture, 659 received
bisphosphonates at the time or after the fracture and 412 used
only one type of bisphosphonate. n-BP (n = 260 alendronate
or risedronate) and etidronate users (n = 114) were matched
1:2 to women who never used osteoporosis treatment follow-
ing fracture. Treated and not treated participants had similar
baseline characteristics; however, individuals on treatment
had a higher estimated 5-year fracture risk than those not
treated (p value < 0.0001 for both n-BP and etidronate pairs).
In women with incident fracture, use of n-BP was associ-
ated with better survival [HR, 0.49 (0.29–0.80)] while etidro-
nate was not associated with survival benefit [HR, 0.82 (95%
CI, 0.46–1.49)] (Fig. 4).
The relationship between n-BP and mortality was similar
regardless of the time of its initiation: HR, 0.48 (95% CI,
0.27–0.85), 0.41 (95% CI, 0.11–1.57) and 0.53 (95% CI,
0.10–2.76) for 0–2, 2–5 and 5+ years post-fracture,
respectively).
The risk of a further fragility fracture was similar for BP
and matched NoRx [HR, 1.20 (95% CI, 0.74–1.94)] and eti-
dronate [HR, 1.55 (95% CI, 0.78–3.11)].
Discussion
Individuals with osteoporotic fracture are at increased risk of
death. Emerging evidence suggests that bisphosphonate treat-
ment of those with an osteoporotic fracture is associatedwith a
reduction of all-cause mortality; however, the mechanism for
this association is unknown. In this observational study, we
found that participants on the nitrogen bisphosphonates,
alendronate and risedronate, experienced a 40% survival ben-
efit, particularly in women. Participants on non-n-BP, etidro-
nate had no overall survival benefit. These findings were fur-
ther supported by a head to head comparison which demon-
strated that nitrogen bisphosphonate users had ~ 50% better
survival compared to etidronate users.
These findings suggest that the benefit seen with the nitro-
gen bisphosphonates either lies in their greater anti-resorptive
effect or via a non-bone effect that may be related to their
disruption of the mevalonate kinase pathway [36]; however,
most importantly, this analysis in a population-based cohort of
two different bisphosphonate biochemistries meant that user
bias played a less significant role in the different outcomes
observed, thus increasing the likelihood that there is a true
decrease in mortality associated with use of nitrogen
bisphosphonates.
The magnitude of mortality reduction associated with ni-
trogen bisphosphonates [HR 0.66 (95% CI, 0.48–0.9 [1]] in
this study, is comparable to previous studies on all-cause mor-
tality risk [15, 16, 18, 37]. In the Dubbo Osteoporosis
Epidemiology Study, bisphosphonate use in women was as-
sociated with a 69% reduction in mortality risk compared to
no treatment [16]. Another study reported 27% lower mortal-
ity in institutionalised older people [38], and two other studies
reported a survival benefit of bisphosphonates in critically ill
people [18, 37]. In a Danish database study, the association
between bisphosphonates and mortality following hip fracture
was similar to this study [15], while two other previous pro-
spective cohort studies reported a stronger relationship (~ 63–
66%) with mortality risk reduction [13, 17]. The differences
between these results are most likely related to differences in
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Fig. 3 Kaplan Meier survival curves for nitrogen bisphosphonate (n-BP:
alendronate or risedronate) and etidronate versus matched not treated in
individuals with incident fracture
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baseline characteristics between the treated and non-treated
populations. Importantly, these findings are also consistent
with the 28%mortality risk reduction observed in the zoledro-
nic acid RCT [11].
The role of etidronate on mortality risk reduction was less
clear. Our primary analysis, with participants who only used
etidronate during the follow-up, showed no survival benefit
over the follow-up period. By contrast, in a sensitivity analy-
sis, including a large number of participants who switched
during follow-up to either alendronate or risedronate, etidro-
nate was associated with ~ 31%mortality risk reduction; how-
ever, this finding has to be interpreted in the light of the im-
mortal time bias inherently induced by longer follow-up with
participants being alive to switch treatments. In addition,
based on the previous analyses, the benefit in etidronate
‘switchers’ could also be attributed to the n-BP to which they
were switched.
The uptake of bisphosphonate by men in this study was
very low in comparison to women. The association in men
between bisphosphonate use and mortality risk was in a sim-
ilar direction to women, particularly for alendronate and eti-
dronate. The effect of risedronate in men is most likely unre-
liable, due to the joint effects of a very small sample size (n <
50) and a shorter follow-up time. The gender discrepancy in
both use of bisphosphonates as well as survival benefit has
been reported previously [14, 16]. In an Austrian study, only
12% of men compared to 30% of women reported initiation of
bisphosphonate therapy following hip fracture. The associa-
tion between bisphosphonates and survival was lower than
that for women, perhaps driven by the smaller number of
men [14].
The mechanism through which bisphosphonates may re-
duce mortality risk is likely to be multifactorial. The most
obvious mechanism would be through a reduction in subse-
quent fracture risk; however, the RCT of zoledronic acid in
women with hip fracture showed that only 8% of the mortality
risk reduction in the treatment group was attributable to a
reduction in the subsequent fracture rate [39]. Similarly, re-
duction in subsequent fracture risk in the current study did not
account for the observed mortality risk reduction. The lack of
a significantly lower subsequent fracture risk reduction in the
treated groups is probably due to their higher baseline fracture
risk and possibly the survival advantage providing more time
to sustain a fracture.
It is also possible, that the relationship between
bisphosphonates and mortality risk could be mediated through
a reduction in the rate of bone loss, a marker of poor health
and increased mortality [40] in both individuals with [41] and
without fractures [42, 43]. This would also be consistent with
the current finding that mortality reduction was greater with n-
BP than with etidronate; parallel with their greater
antiresorptive effects. On the other hand, there is emerging
evidence that nitrogen bisphosphonates may have anti-
inflammatory [30] and anti-cancer effects [31].
This study has several strengths. The large number of
bisphosphonates users permitted a detailed analysis of
bisphosphonates by biochemistry and mortality as well as
adjusting for a large set of risk factors not available in
registry-based studies; however, there are some limitations.
Treatment was a decision made in clinical care and not ran-
domly allocated, thus part of the observed association could
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Fig. 4 Kaplan Meier survival
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confounding bias, this study employed propensity score
matching which is currently recognised as a valid method to
account for bias in observational studies [44]. Although this
procedure cannot account for unmeasured confounding, the
resultant treatment groups had equal baseline risks for all mea-
sured variables. Furthermore, matching by the time of medica-
tion commencement ensured that the treatment groups started
follow-up around the same calendar time. Furthermore, Kaplan
Meier survival for matched treated versus non-treated did not
diverge until after 6 months, suggesting that pairs were well
matched and had similar mortality risk at initiation of treatment.
It is possible that there was residual unmeasured confound-
ing such as number of medications, severity of co-morbidities
and socio-economic status that could not be accounted for in
this observational study. The cost of the different included
bisphosphonates was not directly addressed in this study;
however, in the main analysis, adjustment was made for edu-
cation as a surrogate of socio-economic status. Furthermore,
medication number did not predict likelihood of receiving
bisphosphonate treatment.
Etidronate was not approved worldwide for the treatment
of osteoporosis. It is a weaker anti-resorptive than nitrogen-
bisphosphonates and is given in a cyclical regime for 2 weeks
every 3 months. Didrocal was a formulation of etidronate
(Didronel) for ease of managing the 2 weeks on each 3months
with calcium provided for the other days. Etidronate was
available before the nBPs and could have been prescribed to
sicker patients; however, this is unlikely to have been the case
as in many jurisdictions, etidronate had to have ‘failed’ or not
been tolerated before n-BPs could be prescribed. Thus n-BPs
were often prescribed to sicker patients. Any such differences
could not be identified or excluded.
Given the yearly collection of data, this study could not ad-
dress the issue of misclassification of exposure due to differ-
ences in treatment adherence. It is possible that some partici-
pants may have been prescribed bisphosphonates between year-
ly questionnaires but did not adhere to treatment for the full year.
In this situation, participants would have been classified as non-
treatment despite a ‘window’ of treatment exposure. These par-
ticipants would have only under-estimated the true effect; how-
ever, the exclusion of participantswho reported bisphosphonates
only once during the study follow-up (~ 10%) and thus more
likely to be non-adherent did not impact the findings.
In summary, compared to no treatment, nitrogen bisphos-
phonate use, particularly in women, was associated with better
survival in this long-term prospective population-based cohort
study irrespective of incident fracture status while etidronate
either lacked or had a minor mortality benefit. This observa-
tion is important as it points toward mechanistic hypotheses
that need to be confirmed in further studies. Importantly, this
study suggests that nitrogen bisphosphonate treatment for os-
teoporosis, whether or not a fragility fracture has occurred,
improves survival irrespective of fracture risk prevention.
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